Navigation Links
PeriGen, Inc. Forms Strategic Alliance with Willis Healthcare to Improve Quality of Care in OB
Date:2/9/2011

ies, which represent the next generation of clinical decision support tools for Obstetrics. Providing real-time, interactive guidance at the patient's bedside, PeriGen's fetal monitor and OB patient record facilitate the delivery of consistent, repeatable high-quality care.

"It is common for insurance brokers to anticipate risk, but Willis is unique in its approach to claims prevention," said Donald A. Deieso, Ph.D., Chairman and CEO of PeriGen. "Recognizing that the most effective guard against medical malpractice claims is high-quality, evidence-based care, Willis has chosen to arm its clients with PeriGen's sophisticated risk management and quality improvement tools. We are proud to collaborate with an insurance broker of Willis' caliber and foresight, and we are honored to have been selected to share our offerings with Willis' client base."

About PeriGen, Inc. PeriGen is a technology-enabled professional services company specializing in risk reduction and clinical quality improvement in Obstetrics and is the only OB-specific risk reduction company to provide solutions which generate immediate, quantifiable and clinical value. Singularly focused on reducing risk and improving financial performance, PeriGen's advanced clinical decision support and fetal monitoring solutions are installed in over 100 hospitals across North America. A pioneer in advanced clinical decision support, PeriGen provides innovative solutions and a full suite of complementary professional and consulting services that reduce risk and improve clinical outcomes. PeriGen is a US corporation headquartered in Princeton, New Jersey, with offices in Canada and Israel. For more information, please visit us at www.perigen.com.

About WillisWillis Group Holdings plc is a leading global insurance broker, developing and delivering professional insurance, reinsurance, risk management, financial and human resource consulting and actuarial se
'/>"/>

SOURCE PeriGen, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Allegheny General Hospital Performs First Liver Transplant
2. Medifast Outperforms American Diabetes Association Diet by Twice the Weight Loss According to Published Study
3. UBC Forms European Advisory Board to Enhance Data Quality of CNS Trials
4. Spirit II Results Support Strength of Boston Scientifics Two Drug-Eluting Stent Platforms
5. XIENCE(TM) V Drug Eluting Stent from Abbott Outperforms Market-Leading Stent in Reducing Major Adverse Cardiac Events at Two Years
6. Exiqon Forms Research Collaboration With M. D. Anderson Cancer Center
7. First Molecular Tem-PCR Test to Identify Multiple Forms of Staph and MRSA Obtains CLIA Certificate
8. InNexus Lead Candidate DXL625 Outperforms Rituxan in Additional Animal Studies
9. Abbotts XIENCE V(TM) Drug Eluting Stent Outperforms TAXUS(R) in Key Efficacy and Safety Endpoints Out to Two Years
10. Raptor Pharmaceuticals Provides Update on Targeting Platforms
11. Huntington Hospital Surgeon Performs First Single Port Resection on Colorectal Cancer Patient in CA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... LA JOLLA, Calif. , Oct. 22, ... RGLS ), a biopharmaceutical company leading ... targeting microRNAs, today announced that it has ... from an ongoing clinical study evaluating RG-101, ... for the treatment of hepatitis C virus ...
(Date:10/20/2014)... 20, 2014  Luoxis Diagnostics, Inc., a subsidiary ... announced that its academic collaborators will present several ... for its novel RedoxSYS Diagnostic System, a first-in-class ... body in response to injury or illness.  A ... a clinical marker will be presented by ...
(Date:10/20/2014)... PRINCETON, N.J. , Oct. 20, 2014 /PRNewswire/ ... Taiho Pharmaceutical Co., Ltd. ( Japan ... Administration (FDA) granted Fast Track designation for TAS-102 ... combination anticancer drug under investigation for the treatment ... the Company has initiated a rolling NDA submission ...
Breaking Medicine Technology:A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 2A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 3A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 4A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 5A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 6A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 7A Single Subcutaneous Dose of 2mg/kg of RG-101, Regulus' Wholly-Owned, GalNac-Conjugated anti-miR Targeting microRNA-122, Demonstrates 4.1 log10 Mean Viral Load Reduction as Monotherapy at Day 29 in Patients with Varied HCV Genotypes and Treatment H 8Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 2Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 3Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 4Luoxis to Highlight RedoxSYS at Two Upcoming Scientific Conferences 5Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 2Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 3Taiho Oncology, Inc. Receives FDA Fast Track Designation for TAS-102 as a Potential Treatment for Refractory Metastatic Colorectal Cancer 4
... 2012 The U.S. Food and Drug Administration today ... by W.L. Gore and Associates Inc. to include treatment ... aortic transection). (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... endovascular graft approved by the FDA to treat a ...
... CHAPEL HILL, N.C., Jan. 13, 2012  Facing patent cliffs ... alliances - either through in-licensing deals or M&A activities ... It,s a sound strategy, but a difficult one to ... and consummating a business is fraught with potential pitfalls. ...
Cached Medicine Technology:FDA Expands Use of Endovascular Graft to Treat Aortic Tears 2Excellence Services Program Delivers a Road Map to Successfully Guide the Pharmaceutical Industry Through the New Alliance Landscape 2
(Date:10/20/2014)... York, NY (PRWEB) October 20, 2014 ... be introduced in the U.S., has a lot to celebrate ... when our country recognizes the achievements and contributions of Americans ... the anniversary for Punzoné, and today it shares its favorite ... take a trip to Italy - even if it is ...
(Date:10/19/2014)... (PRWEB) October 20, 2014 Hastings and ... 30 years of service throughout the greater Phoenix area ... legal representation with regard to catastrophic automobile accidents. Statistics ... the country and throughout Arizona. As such, Hastings and ... for legal representation for those who have been injured ...
(Date:10/19/2014)... York (PRWEB) October 19, 2014 Dr. ... Population Fund, welcomes news of a ceasefire agreement that ... more than 200 girls who were kidnapped from the ... have languished in captivity long enough, and it is ... and communities," stated Dr. Osotimehin. , "We owe it ...
(Date:10/19/2014)... October 20, 2014 Recently, Top10BestSEOHosting.com ... announced that JustHost, GoDaddy and HostMonster are the ... VPS (Virtual Private Server) is the method of ... each of which has the appearance and capabilities ... is why the site pays close attention to ...
(Date:10/19/2014)... 2014 Visual Impact Frequency Training ... been released to the public generating a frenzied ... and fitness community. The commotion surrounding the program's ... Delmonico prompting an investigative review. , "Many gym-goers ... is commonly known as a training 'plateau' where ...
Breaking Medicine News(10 mins):Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 2Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 3Health News:Celebrate Italian Heritage Month With Authentic Cocktails from Punzoné: The Only Ultra Premium Line of Organic Imported Italian Vodka 4Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 3Health News:The Best VPS Hosting Suppliers In The Market Unveiled By Top10BestSEOHosting.com 2Health News:Visual Impact Frequency Training Review: Rusty Moore's Latest Fitness Guide Released 2
... 3rd Advocacy Day, WASHINGTON, March 10 ... Lupus Research (ALR), on behalf of the 1.4,million ... the,disease to their Members of Congress. ALR Advocates ... asked their Members to,support lupus research funding through ...
... KENILWORTH, N.J., March 10 Schering-Plough,Corporation (NYSE: SGP ... presentation,by Fred Hassan, chairman and Chief Executive Officer, at ... Fla., on,Tuesday, March 18, at approximately 10:15 a.m. (ET). ... the integration of Organon,BioSciences N.V., acquired in November 2007., ...
... PORTLAND, Ore. A team of researchers at Oregon ... Louis have described for the first time the mechanism ... engineered and patented the potential to become ... The team described how their genetically modified enzyme, called ...
... Review found vets with the syndrome were more exposed ... News) -- A new scientific review finds a strong ... War illness suffered by many veterans. , The ... found in pesticides, nerve agents and in pills given ...
... SAN FRANCISCO, March 10 The Women,s ... Hickman, MD, was honored with,the prestigious Rose ... the,American Academy of Dermatology meeting held recently ... ), (Logo: http://www.newscom.com/cgi-bin/prnh/20080310/AQM132LOGO-b ), ...
... 10 The Women,s Dermatologic,Society (WDS) is pleased to ... took office at the recent WDS luncheon during the,American ... Dr.,Connolly moved into the presidential role from this past ... the past three years.,Mary P. Lupo, MD, served as ...
Cached Medicine News:Health News:Working Together for a Cure 2Health News:Working Together for a Cure 3Health News:Key found to breakthrough drug for clot victims 2Health News:Key found to breakthrough drug for clot victims 3Health News:Gulf War Illness Strongly Linked to Chemical Exposure 2Health News:Gulf War Illness Strongly Linked to Chemical Exposure 3Health News:Lynchburg, VA Dermatologist Janet G. Hickman, MD Honored With Rose Hirschler Award from Women's Dermatologic Society 2Health News:Suzanne M. Connolly, MD Named 2008-2009 President of Women's Dermatologic Society 2
45 degree, forward 3 mm, 4 mm x 5 mm cup, length of shaft 140 mm, overall length 8.3 inches....
22 mm. Plastic, methylmethacrylate, lightweight. Supplied sterile....
Size: Small. 20.50 mm by 22.00 mm. Clear lucite. Supplied sterile....
... x 7.5 x 80 mm. Storz ... line designed by Harvey A. Lincoff, ... closed cell sponge which is non-toxic ... rounded edges to minimize scleral intrusion. ...
Medicine Products: